Ask about this productRelated genes to: FGF23 protein
- Gene:
- FGF23 NIH gene
- Name:
- fibroblast growth factor 23
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 12p13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-16
- Date modifiied:
- 2016-10-05
Related products to: FGF23 protein
Related articles to: FGF23 protein
- Global aging and the growing burden of age-related disease have intensified interest in modifiable biomarkers of biological age. -Klotho, the product of the KL gene, is a pleiotropic anti-aging protein whose circulating (soluble, s-Klotho) form declines with age and is independently associated with all-cause mortality, sarcopenia, cognitive deficit, and cardiovascular events. We conducted a systematic review and meta-analysis of publications from 2015 to 2025 evaluating the effect of exercise training [aerobic, resistance, high-intensity interval training (HIIT), combined] on circulating α-Klotho in adults, with emphasis on individuals aged ≥60 years and patients with chronic kidney disease (CKD), diabetes, and sarcopenia. - Source: PubMed
Publication date: 2026/09/03
Abduldayeva Aigul AIskakova Saule ADoszhanova Gulnur NSafonov Nikolay ATuliyeva Aliya M - - Source: PubMed
Publication date: 2026/09/18
Zöchbauer LeoHöbaus ClemensZierfuss Bernhard - - Source: PubMed
Publication date: 2026/09/18
Zöchbauer LeoHöbaus ClemensZierfuss Bernhard - Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been used as a therapy for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD); however, their effects on erythropoiesis, phosphate regulation, and bone turnover are incompletely clarified. Studies report a marked increase in hemoglobin and hematocrit during treatment, suggesting an erythropoietic response rather than simple hemoconcentration. Simultaneously, changes in mineral metabolism, including a modest increase in phosphate, fibroblast growth factor-23 (FGF-23), and parathyroid hormone (PTH), raise questions about the possible consequences for bone quality, mainly in individuals with diabetes or CKD who are at increased risk of fracture. Accordingly, this narrative review was structured through a literature search of PubMed, Scopus and Google Scholar for studies published in English up to November 2025. Keywords included SGLT2 inhibitors, erythropoiesis, bone metabolism, phosphate homeostasis, FGF-23, PTH, vitamin D, bone mineral density (BMD) and fracture. Randomized trials, mechanistic studies, animal experiments, observational cohorts, sub-analysis and reviews were included. Current evidence shows that SGLT2 inhibition promotes erythropoietin production, enhances iron mobilization and modifies the bone marrow environment, while also influencing the FGF- 23-PTH-vitamin D axis through renal phosphate handling. Although canagliflozin has been associated with reduction in hip BMD and possible fracture risk, findings from the drug class remain inconsistent and are often confounded by baseline comorbidities. In conclusion, SGLT2 inhibitors trigger a connected hematologic and mineral changes, but their long-term skeletal impact remains uncertain. Further mechanistic and longitudinal studies are advised to clarify these outcomes. - Source: PubMed
Publication date: 2026/08/31
Mohammad Aseel HMohammad Shatha HAlsaaty Mohammad H - Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a severe complication of chronic kidney disease characterized by dysregulation of the FGF-23/Klotho axis. MicroRNA-340-5p (miR-340-5p) participates in this signaling pathway. Nevertheless, its functional role in CKD-MBD, as well as the underlying mechanism by which Yishen Huayu Formula (YSHYF) intervenes in this disease, remains unclear. - Source: PubMed
Publication date: 2026/09/15
Zhao LiangLiu WenjingChen KailiXiao ChangbinZhang LinqiChen Guanting